Home
About us
Corporate Profile
Awards and Qualification
Social Responsibility
Diseases and solutions
Cardiovascular diseases
Uncontrolled and Resistant Hypertension
Peripheral Artery Disease
Vascular calcification (VC)
Product Center
Bioresorbable Scaffolds (BRS) and Ancillary Products
Renal Denervation (RDN)
Investor Relations
Corporate Information
Corporate Governance
Financial Reports
Performance Report
Prospectus
Announcements and Circulars
Investor Enquiries
News Center
News
Video
Contact us
Contact Us/Recruitment
简 / 繁 / EN
简体中文
繁體中文
English
News Center
Keep up to date with our news
Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023
2023-06-30
上一页
1
下一页